Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial
Loading...
Date
2022-07-19
Journal Title
Journal ISSN
Volume Title
Publisher
The Lancet HIV
Abstract
Children with HIV-associated tuberculosis (TB) have few antiretroviral therapy (ART) options. We aimed to evaluate the safety and pharmacokinetics of dolutegravir twice-daily dosing in children receiving rifampicin for HIV-associated TB.
Description
Keywords
Citation
Turkova, A., Waalewijn, H., Chan, M. K., Bollen, P. D., Bwakura-Dangarembizi, M. F., Kekitiinwa, A. R., ... & Greetanukroh, P. (2022). Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial. The Lancet HIV, 9(9), e627-e637.